Suven Discovery Scientific Presentations in 2009

American Chemical Society (ACS)

March 22 - 26, 2009, Salt Lake City, UT, USA

1. Novel aryl sulfonamides: A new chemical class of selective 5-HT_6 receptor antagonists.

   A. Shinde, *et al.,*

2. Conformationally restricted tryptamine sulfonamides as novel and selective 5-HT_6 receptor antagonists.

   J. Konda, *et al.,*

3. Pummerer reaction as the key step in the stereoselective synthesis of D-ribo-(2S,3S,4R)-Phytosphingosine.

   M. Rasheed, *et al.,*

International Conference on Alzheimer's Disease (ICAD)

July 11 - 16, 2009, Vienna, Austria

4. Safety, tolerability and pharmacokinetics of SUVN-502: A 5-HT_6 receptor antagonist first in human phase-1 single ascending (SA) dose study.

   R. Nirogi, *et al.,*

5. Human phase-1 multiple ascending (MA) dose study: Safety, tolerability and pharmacokinetics of a potent 5-HT_6 receptor antagonist SUVN-502.

   R. Nirogi, *et al.,*

6. SUVN-502: A safe, potent, selective, brain penetrant and orally active 5-HT_6 receptor antagonist – First in human clinical phase-1 study.

   R. Nirogi, *et al.,*

7. SUVN-502: A potent, selective, brain penetrant and orally active 5-HT_6 receptor antagonist.

   R. Nirogi, *et al.,*

American Chemical Society (ACS)

August 16 - 20, 2009, Washington, DC, USA

8. Tetrahydrocarbazole derivatives as novel and selective 5-HT_6 receptor ligands.

   J. Konda, *et al.,*

9. Novel piperazine analogs as potent and selective 5-HT_6 receptor ligands.

   R. Badange, *et al.,*

10. Functionalization of Olefins by pendant sulfoxide: Towards stereoselective synthesis of D-ribo-(2S,3S,4R)-Phytosphingosine.

    A. Rasheed, *et al.,*

Society For Neuroscience (SFN)

October 17-21, 2009, Chicago, USA

11. DRL-72s: Scopolamine induced deficits and its reversal by choline esterase inhibitors.

    P. Jayarajan*, et. al.*

12. Brain distribution of methyllycaconitine: A potent and selective neuronal nicotinic acetylcholine receptor antagonist.

    G. Bhyrapuneni, *et. al.,*

13. SUVN-911: A potent and selective nicotinic acetylcholine receptor antagonist in animal models of depressive disorders.

    ***R. Nirogi**, et. al.,*

14. Measurement of intracellular calcium ions in neuronal IMR32 cells expressing recombinant aequorin gene.

    ***I. Ahmad**, et. al.,*

15. Comparison of different class of H3 receptor antagonists to enhance cortical histamine levels.

    ***V. Kandikere**, et. al.,*

16. SUVN-623: A 5-HT_6 antagonist in animal models of cognition.

    ***R. Abraham**, et. al.,*

ISSX North American Regional Meeting 2009

October 18-22, 2009, Baltimore, Maryland, USA

17. CYP2D6 and CYP3A4 inhibitory potential of marketed CNS drugs from LC-MS/MS and fluorescent based assays.

    ***V. Kandikere,** et. al.,*

18. Screening for reactive drug metabolites in establishing structure metabolite relationship during drug development.

    ***G. Bhyrapuneni,** et. al.,*

19. Pharmacokinetics of Sarpogrelate following single intravenous or oral administration in rats.

    ***R. Nirogi,** et. al.,*

AAPS Annual Meeting and Exposition 2009

November 8-12, 2009, Los Angeles, CA, USA

20. Micro-formulation approach for in vivo screening of NCE's in drug discovery.

    Y. Gupta, *et. al.,*

21. Pharmacokinetics of Sarpogrelate following single intravenous or oral administration in rats.

    N. Muddana, *et. al.,*